PHP
INZY

Parkman Healthcare Partners’s Inozyme Pharma INZY Stock Holding History

Parkman Healthcare Partners’s Portfolio INZY Stock Details INZY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-222,943
Closed -$1.71M – 101
2024
Q1 		$1.71M Buy
222,943
+10,511
+5% +$57.7K 0.21% 88
2023
Q4 		$905K Buy
212,432
+36,536
+21% +$130K 0.13% 81
2023
Q3 		$739K Buy
175,896
+7,106
+4% +$36.1K 0.14% 95
2023
Q2 		$940K Buy
168,790
+43,790
+35% +$259K 0.16% 87
2023
Q1 		$716K Buy
+125,000
New +$330K 0.16% 75

Other funds holding INZY

Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
PBPIA
Pivotal bioVenture Partners Investment Advisor San Francisco, California $280M AUM 181.4% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
SC
Samlyn Capital New York $5.86B AUM 36.3% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Parkman Healthcare Partners's INZY Position: Q2 2024 in Review

Parkman Healthcare Partners sold out of Inozyme Pharma (INZY) in Q2 2024, closing a stake of 222,943 shares — an estimated $1.71M sold.

Parkman Healthcare Partners first reported a position in INZY in Q1 2023 and held it in 5 quarters. The position peaked at $1.71M in Q1 2024. 90 funds tracked by Wall St. Rank hold INZY as of Q2 2024.

  • Parkman Healthcare Partners reported no remaining Inozyme Pharma position as of Q2 2024 after selling out during the quarter.
  • Parkman Healthcare Partners sold 222,943 Inozyme Pharma shares in Q2 2024, an estimated $1.71M.
  • Parkman Healthcare Partners first reported a position in Inozyme Pharma in Q1 2023 and held it in 5 quarters.
  • Parkman Healthcare Partners's Inozyme Pharma position peaked at $1.71M in Q1 2024.
  • 90 funds tracked by Wall St. Rank held Inozyme Pharma as of Q2 2024.

Based on Parkman Healthcare Partners's 13F filing for Q2 2024, filed 14 Aug 2024.